Free Trial

Lantheus (LNTH) Competitors

$81.83
+1.31 (+1.63%)
(As of 05/31/2024 ET)

LNTH vs. RIOT, QDEL, NEOG, CLDX, NTLA, MYGN, ACHV, TKNO, VNRX, and ABIO

Should you be buying Lantheus stock or one of its competitors? The main competitors of Lantheus include Riot Platforms (RIOT), QuidelOrtho (QDEL), Neogen (NEOG), Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Achieve Life Sciences (ACHV), Alpha Teknova (TKNO), VolitionRx (VNRX), and ARCA biopharma (ABIO).

Lantheus vs.

Riot Platforms (NASDAQ:RIOT) and Lantheus (NASDAQ:LNTH) are both mid-cap business services companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, community ranking, risk and media sentiment.

In the previous week, Riot Platforms had 3 more articles in the media than Lantheus. MarketBeat recorded 12 mentions for Riot Platforms and 9 mentions for Lantheus. Riot Platforms' average media sentiment score of 0.92 beat Lantheus' score of -0.49 indicating that Lantheus is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Riot Platforms
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
7 Very Negative mention(s)
Neutral
Lantheus
5 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lantheus has higher revenue and earnings than Riot Platforms. Riot Platforms is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Riot Platforms$280.70M10.02-$49.47M$0.8711.20
Lantheus$1.30B4.37$326.66M$6.5512.49

Riot Platforms currently has a consensus price target of $18.15, indicating a potential upside of 86.30%. Lantheus has a consensus price target of $99.17, indicating a potential upside of 21.19%. Given Lantheus' stronger consensus rating and higher possible upside, research analysts plainly believe Riot Platforms is more favorable than Lantheus.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Riot Platforms
0 Sell rating(s)
0 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
3.00
Lantheus
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Riot Platforms received 171 more outperform votes than Lantheus when rated by MarketBeat users. Likewise, 67.43% of users gave Riot Platforms an outperform vote while only 65.21% of users gave Lantheus an outperform vote.

CompanyUnderperformOutperform
Riot PlatformsOutperform Votes
499
67.43%
Underperform Votes
241
32.57%
LantheusOutperform Votes
328
65.21%
Underperform Votes
175
34.79%

40.3% of Riot Platforms shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 4.4% of Riot Platforms shares are owned by company insiders. Comparatively, 1.5% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Riot Platforms has a net margin of 76.02% compared to Riot Platforms' net margin of 33.72%. Riot Platforms' return on equity of 54.10% beat Lantheus' return on equity.

Company Net Margins Return on Equity Return on Assets
Riot Platforms76.02% 12.56% 11.66%
Lantheus 33.72%54.10%25.70%

Riot Platforms has a beta of 4.19, indicating that its stock price is 319% more volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500.

Summary

Riot Platforms beats Lantheus on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LNTH vs. The Competition

MetricLantheusDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$5.67B$2.83B$5.18B$7.99B
Dividend YieldN/A0.71%2.77%4.00%
P/E Ratio12.49152.99139.9218.59
Price / Sales4.3780.662,392.6077.18
Price / Cash12.1316.5835.6531.55
Price / Book6.003.595.554.59
Net Income$326.66M$32.98M$106.13M$213.90M
7 Day Performance4.62%-0.53%1.15%0.87%
1 Month Performance4.67%1.03%0.65%1.82%
1 Year Performance-7.71%-28.11%2.66%5.90%

Lantheus Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RIOT
Riot Platforms
3.1475 of 5 stars
$10.00
-3.3%
$18.33
+83.3%
-21.5%$2.99B$280.70M11.49534Analyst Forecast
QDEL
QuidelOrtho
4.2757 of 5 stars
$43.71
-0.8%
$59.00
+35.0%
-48.4%$2.95B$3.00B-1.667,100
NEOG
Neogen
3.4486 of 5 stars
$13.17
-2.6%
$22.50
+70.8%
-29.0%$2.93B$822.45M1,318.322,640Positive News
CLDX
Celldex Therapeutics
1.4617 of 5 stars
$34.22
-3.3%
$66.00
+92.9%
+3.6%$2.33B$6.88M-12.01160Short Interest ↓
Positive News
NTLA
Intellia Therapeutics
3.759 of 5 stars
$21.67
-4.6%
$66.77
+208.1%
-44.0%$2.19B$36.28M-4.04526Analyst Revision
Positive News
Gap Down
High Trading Volume
MYGN
Myriad Genetics
3.4312 of 5 stars
$22.70
-2.7%
$25.57
+12.6%
-1.5%$2.11B$753.20M-8.052,700Positive News
Gap Down
ACHV
Achieve Life Sciences
1.6064 of 5 stars
$5.34
-0.4%
$14.00
+162.2%
-19.2%$184.07MN/A-4.1422
TKNO
Alpha Teknova
3.0832 of 5 stars
$1.75
-1.1%
$15.00
+757.1%
-54.8%$72.46M$36.68M-1.67210Short Interest ↓
Positive News
Gap Down
VNRX
VolitionRx
0.5526 of 5 stars
$0.76
+11.8%
$2.50
+229.4%
N/A$56.32M$770,000.00-1.65110Analyst Forecast
Gap Up
ABIO
ARCA biopharma
0 of 5 stars
$3.43
-3.4%
N/A+76.2%$51.50MN/A-8.174

Related Companies and Tools

This page (NASDAQ:LNTH) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners